Generics - Forest Laboratories, Generics


Popular Filters

Actavis and Forest to divest four generics to gain FTC OK for merger


In order for Ireland-headquartered generics major Actavis to complete its previously-announced $25 billion…

ActavisForest LaboratoriesGeneric pharmaceuticalsGenericsHealth Medical PharmaMedicinePharmaceutical industryPharmacologyRegulationUSA

Actavis confirms plan to acquire Forest Labs for about $25 billion

Actavis confirms plan to acquire Forest Labs for about $25 billion


After a morning of speculation and rumors, generics drug major Actavis today confirmed that it has reached…

ActavisForest LaboratoriesGenericsMergers & AcquisitionsPharmaceutical

Forest Labs settles Bystolic litigation with Actavis


US drugmaker Forest Laboratories has entered into a settlement agreement with generics drug major Actavis…

ActavisBystolicCardio-vascularForest LaboratoriesGenericsLegalNorth AmericaPatents

Lundbeck/Takeda's Brintellix has blockbuster potential


Denmark CNS drug specialist Lundbeck (LUND: CO) and partner Japanese drug major Takeda Pharmaceutical's…

BrintellixedivoxetineEli LillyFetzimaForest LaboratoriesGenericsGlobalLundbeckMarkets & MarketingNeurologicalPharmaceuticalPierre FabreTakeda Pharmaceuticals

Amerigen collaborates with Forest Labs


US generics drugmaker Amerigen Pharmaceuticals has entered into a collaboration agreement with Forest…

Amerigen PharmaceuticalsForest LaboratoriesGenericsNorth AmericaProduction

Forest agrees another license deal for Bystolic


US drugmaker Forest Laboratories (NYSE:FRX) and Forest Laboratories Holdings have reached a settlement…

Amerigen PharmaceuticalsBystolicCardio-vascularForest LaboratoriesGenericsLicensingNorth AmericaPharmaceutical

Drugmakers to continue facing growing generic competition in 2013


Last year saw the expiration of patents for several blockbuster drugs, leading to increasing generic…

AmarinFinancialForest LaboratoriesGenericsPatentsPharmaceutical

Insights on the US Alzheimer's disease market


The treatment of Alzheimer's disease (AD) offers a compelling commercial opportunity for the pharmaceutical…

AriceptEisaiExelonForest LaboratoriesGenericsMarkets & MarketingNamendaNeurologicalNorth AmericaNovartisPfizerPharmaceutical

Forest Labs links with moksha8 for Viibryd in Latin America; Watson sells minority stake


US drugmaker Forest Laboratories (NYSE: FRX) has entered into a broad strategic alliance with Brazil-based…

Forest LaboratoriesGenericsLicensingMergers & AcquisitionsMoksha8NeurologicalPharmaceuticalSouth AmericaViibrydWatson Pharmaceuticals

Forest Labs cuts FY 2013 earnings forecasts on Lexapro woes


Following the expiration of US drugmaker Forest Laboratories' (NYSE: FRX) once best-selling anxiety drug…

FinancialForest LaboratoriesGenericsLevothroidLexaproPharmaceutical



Back to top